We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
FIGURE 2

FIGURE 2. From: Abnormalities of Dorsolateral Prefrontal Function in Women With Premenstrual Dysphoric Disorder: A Multimodal Neuroimaging Study.

Between-Group Differences of PET and fMRI Activation in a Multimodal Neuroimaging Study of Premenstrual Dysphoric Disordera
a Panel A shows the between-group differences in activation (2-back > 0-back) using PET and fMRI. Regions in which patients had greater activation than comparison subjects are shown in pink. Panel B shows the correlations between Global Assessment of Functioning Scale (GAF) scores and activation in patients using PET and fMRI. Regions in which these two measures were negatively correlated (the greater the overactivation, the more severe impairment indicated by GAF scores) are shown in blue. For all analyses: p<0.05, false discovery rate corrected; extent threshold=50.

Erica B. Baller, et al. Am J Psychiatry. 2013 March 1;170(3):305-314.
2.
FIGURE 3

FIGURE 3. From: Abnormalities of Dorsolateral Prefrontal Function in Women With Premenstrual Dysphoric Disorder: A Multimodal Neuroimaging Study.

Convergence of PET and fMRI Activation, Hormone Condition, Age, and Functioning in a Multimodal Neuroimaging Study of Premenstrual Dysphoric Disordera
a In the top panels, PET and fMRI scan overlays illustrate the convergence between regions in which patients showed overactivation (pink) and regions in which their activations correlated with their Global Assessment of Functioning Scale (GAF) scores (light blue); overlap is indicated in dark blue; p<0.05, false discovery rate corrected, extent threshold=50. The graphs on the right depict data for each individual by hormonal condition for PET (panel A) average rCBF from a 4-mm sphere centered at coordinates x=36, y=54, and z=4 and for fMRI (panel B) average BOLD signal from a 4-mm sphere centered at coordinates x=44, y=42, and z=28. Circles enclose the maximal voxel in activation-GAF score correlation maps within the dorsolateral prefrontal cortex mask, from which extracted values are plotted for each hormone condition separately. In the bottom panels, PET and fMRI scan overlays illustrate the convergence between regions in which patients showed overactivation (pink) and regions in which their activations correlated with their age at onset (light blue); overlap is indicated in dark blue; p<0.05, false discovery rate corrected, extent threshold=50. The graphs on the right show data for each individual by hormonal condition for PET (panel C) average rCBF from a 4-mm sphere centered on coordinates x=48, y=40, and z=20 and for fMRI (panel D) average BOLD signal from a 4-mm sphere centered on coordinates x=46, y=42, and z=24. Circles enclose the maximal voxel in activation-age at onset correlation maps within the dorsolateral prefrontal cortex mask, from which extracted values are plotted for each hormone condition separately.

Erica B. Baller, et al. Am J Psychiatry. 2013 March 1;170(3):305-314.
3.
FIGURE 1

FIGURE 1. From: Abnormalities of Dorsolateral Prefrontal Function in Women With Premenstrual Dysphoric Disorder: A Multimodal Neuroimaging Study.

Study Schematic and Timing of PET and fMRI Procedures in a Multimodal Neuroimaging Study of Premenstrual Dysphoric Disordera
a All participants received injections of the gonadotropin-releasing hormone agonist leuprolide at a dosage of 3.75 mg i.m. every 4 weeks. Plasma follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone levels were measured at each study visit to confirm adequate gonadal suppression. After 3 months of unopposed leuprolide, all participants entered the hormonal add-back phase while continuing to receive monthly leuprolide injections. The women were randomly assigned to receive 5 weeks each of transdermal 17β-estradiol at a dosage of 0.1 mg per day or progesterone vaginal suppositories at a dosage of 200 mg b.i.d. in a double-blind, placebo-controlled crossover fashion with a 2-week washout period between the periods of hormone administration. In addition, during the fifth week of estradiol, all women received both estradiol and progesterone to induce menses. During the hormone add-back phases, women received both patches and suppositories each day (active or placebo, according to add-back phase) in order to blind the treatment team and participants to the hormone being replaced. Scanning windows are indicated by the yellow bars.

Erica B. Baller, et al. Am J Psychiatry. 2013 March 1;170(3):305-314.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk